Safety of Accelerated Schedules of Subcutaneous Allergen Immunotherapy with House Dust Mite Extract in Patients with Atopic Dermatitis.
10.3346/jkms.2011.26.9.1159
- Author:
Myoung Eun KIM
1
;
Jeong Eun KIM
;
Joon Mo SUNG
;
Jin Woo LEE
;
Gil Soon CHOI
;
Dong Ho NAHM
Author Information
1. Department of Allergy and Clinical Immunology, Ajou University Hospital, Suwon, Korea. donghonahm@yahoo.co.kr
- Publication Type:Research Support, Non-U.S. Gov't ; Original Article
- Keywords:
Allergens;
Desensitization;
Dermatitis, Atopic;
Bronchial Asthma;
Adverse Effects;
Dermatophagoides;
Pyroglyphidae
- MeSH:
Adolescent;
Adult;
Allergens/*therapeutic use;
Aluminum Hydroxide/chemistry;
Animals;
Asthma/therapy;
Dermatitis, Atopic/immunology/*therapy;
Desensitization, Immunologic/*methods;
Drug Administration Schedule;
Female;
Humans;
Infusions, Subcutaneous;
Male;
Pyroglyphidae/*immunology/metabolism
- From:Journal of Korean Medical Science
2011;26(9):1159-1164
- CountryRepublic of Korea
- Language:English
-
Abstract:
The safety of accelerated schedules of allergen immunotherapy (ASAI) in patients with bronchial asthma (BA) has been reported but there are little data on the safety of ASAI for patients with atopic dermatitis (AD). In this study, we investigated the safety of ASAI in patients with AD. Sixty patients with AD and 18 patients with BA sensitized to house dust mites (HDM) were studied. A maximum maintenance dose of HDM extract, adsorbed to aluminum hydroxide, was administered to patients by subcutaneous injection with either a 3-day protocol (rush immunotherapy) or 1-day protocol (ultra-rush immunotherapy). Systemic reactions were observed 4 of 15 patients (26.7%) with AD during rush immunotherapy, 13 of 45 patients (28.9%) with AD during ultra-rush immunotherapy, and 4 of 18 patients (22.2%) with BA during rush immunotherapy (P > 0.05). No severe or near fatal systemic reactions occurred in 78 subjects of this study. Systemic reactions developed within 4 hr after administration of the maximum allergen dose in 20 of 21 patients (95.2%) with AD and BA who showed systemic reactions during rush or ultra-rush immunotherapy. In conclusion, ASAI was safe and well tolerated in patients with AD. ASAI can be a useful therapeutic option for AD.
